Fig. 1 · Structure

Documents & Downloads

Galanthamine hydrobromide

Cat. No. A10416 CAS 1953-04-4

AChE inhibitor

Galanthamine is an AChE inhibitor with IC50 of 14 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Galanthamine hydrobromide inhibited electric-eel acetylcholinesterase with a reported IC50 of 1.45 µg/mL in a modified Ellman assay. Substrate-variation experiments supported competitive inhibition under the tested conditions. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

In recombinant human nicotinic receptor assays, galantamine hydrobromide did not significantly potentiate ACh-evoked currents in the tested oocyte systems. HEK293 cells expressing human α7 receptors likewise showed no positive modulation at 10 nM–10 µM; higher concentrations inhibited responses. These findings limit claims of nicotinic potentiation in these models. [2]

Electric-eel AChE inhibition

Biochemical assay · Isolated Electrophorus electricus acetylcholinesterase, type VI-S [1]

Galantamine hydrobromide was the positive-control inhibitor in a modified Ellman assay. The reported IC50 is an assay endpoint, not a treatment dose.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of acetylthiocholine hydrolysisIC50 1.45 µg/mL[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.01–100 µg/mL positive-control concentration range
Exposure duration
30 min pre-incubation at 37 °C; 20 min substrate reaction; 10 min color development
Method
Modified Ellman assay; electric-eel AChE; acetylthiocholine substrate; phosphate buffer pH 8; inhibition calculated relative to activity without inhibitor with matched negative-control subtraction.
Vehicle
Positive control in water for screening; serial dilutions in phosphate buffer for IC50 determination.
Co-treatment
None; galantamine tested alone as the positive control.
Reported limits
No IC50 confidence interval or distinction between technical and independent triplicates. No Adooq lot testing.
Methods and source locations

Compound reported in the paper: Galantamine hydrobromide; Compound label in the paper: Positive control

Results apply to the named hydrobromide reagent in this assay; supplier provenance does not establish Adooq use.

Results 2.2; Table 1; Figure 2; Methods 3.1, 3.3–3.4

Inhibition of acetylthiocholine hydrolysis: Modified Ellman assay, 412 nm; experiments in triplicates; no uncertainty interval for this IC50 is supplied in Table 1. — Table 1, galantamine hydrobromide row; Results 2.2; Figure 2 A–D

Competitive AChE inhibition in substrate-variation experiments

Biochemical assay · Electric-eel AChE with varied acetylthiocholine concentration [1]

The authors classified galantamine hydrobromide inhibition as competitive from substrate-variation kinetics and Lineweaver–Burk plots. The no-inhibitor condition was the comparator.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Substrate-variation kinetic patternInhibition type Competitive[1]

Literature-Reported Treatment Conditions

Treatment concentration
Galantamine hydrobromide 1 and 5 µg/mL; substrate 0.1–1.6 mM
Exposure duration
Shared screening method: 30 min inhibitor pre-incubation, 20 min substrate reaction and 10 min color development
Method
Substrate-variation kinetics with no-inhibitor comparison; 37 °C; 412 nm.
Vehicle
Phosphate buffer
Co-treatment
None; comparator inhibitors were separate conditions.
Reported limits
No Ki is reported for this adopted experiment; no independent confirmation of reversibility was extracted.
Methods and source locations

Compound reported in the paper: Galantamine hydrobromide; Compound label in the paper: Positive control

Results apply to the named hydrobromide reagent in this assay; supplier provenance does not establish Adooq use.

Results 2.4; Table 3; Figure 4A; Methods 3.1, 3.3, 3.6

Substrate-variation kinetic pattern: Lineweaver–Burk plots and Michaelis–Menten fitting; triplicates. — Results 2.4; Table 3; Figure 4A

Nicotinic receptor modulation in oocytes

Cell-based study · Human α7, (α4)3(β2)2, (α4)2(β2)3 and (α4)3(β4)2 nicotinic receptors expressed in Xenopus laevis oocytes [2]

No significant positive modulation of ACh-evoked peak currents was observed over the tested range. Higher concentrations inhibited currents. NS1738 produced detectable positive modulation at α7 as an assay control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ACh-evoked peak current relative to ACh alonePositive modulation No significant increase at tested galantamine concentrations (10 nM–100 µM)[2]

Literature-Reported Treatment Conditions

Treatment concentration
Galantamine 10 nM–100 µM; ACh controls: α7 and (α4)3(β2)2, 30 µM; (α4)2(β2)3, 1 µM; (α4)3(β4)2, 10 µM
Exposure duration
30–40 s galantamine pre-incubation followed by 25–45 s co-application with ACh; timing depended on receptor type
Method
Two-electrode voltage clamp at −60 mV; Ca2+-free standard recording solution; peak currents normalized to prior ACh-only reference.
Vehicle
Water stock diluted freshly in saline
Co-treatment
ACh co-application; NS1738 tested separately as positive modulation control.
Reported limits
These are isolated-cell receptor measurements, not whole-animal efficacy. No robust inhibitory fit was possible for (α4)2(β2)3 at the tested maximum; no IC50 is assigned to that receptor.
Methods and source locations

Compound reported in the paper: Galantamine hydrobromide; Compound label in the paper: Galantamine

Results apply to the named hydrobromide reagent in this assay; supplier provenance does not establish Adooq use.

Figures 1–2; Methods: Oocyte electrophysiology, Experimental protocol for oocyte experiments, Data analysis and Materials; corresponding Results

ACh-evoked peak current relative to ACh alone: Two-electrode voltage clamp, −60 mV; ACh-only reference and NS1738 positive-modulator control at α7. — Results: Testing for modulatory properties of galantamine at nACh receptors expressed in oocytes; Figures 1–2

Human α7 receptor responses in HEK293 cells

Cell-based study · HEK293 cells stably expressing human wild-type α7 nicotinic receptor and RIC3 [2]

Galantamine did not positively modulate ACh-evoked currents at 10 nM–10 µM; inhibition was apparent at 100 µM. The fitted inhibitory IC50 was 64 µM (n = 7 experiments). NS1738 produced positive modulation in the same assay system.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of ACh-evoked α7 peak currentIC50 64 µM (n = 7 experiments)[2]

Literature-Reported Treatment Conditions

Treatment concentration
Galantamine 10 nM–100 µM; ACh 80 µM (approximately EC20)
Exposure duration
40 s pre-application (60 s at 0.01 µM galantamine), then 250 ms co-application with ACh
Method
Whole-cell patch clamp at −70 mV; ACh-only reference; NS1738 positive-modulator control tested separately.
Vehicle
Fresh dilutions in recording buffer
Co-treatment
ACh co-application; NS1738 tested separately.
Reported limits
n denotes complete cell experiments, not animals; datasets obtained on at least two experimental days. No clinical concentration or efficacy inference.
Methods and source locations

Compound reported in the paper: Galantamine hydrobromide; Compound label in the paper: Galantamine

Results apply to the named hydrobromide reagent in this assay; supplier provenance does not establish Adooq use.

Figure 5 A–D; Methods: HEK293 cell patch-clamp electrophysiology, Data analysis and Materials; corresponding Results

Inhibition of ACh-evoked α7 peak current: Whole-cell patch clamp; Hill fit to peak-current responses normalized to prior ACh-only control. IC50 is fitted inhibitory potency, not the applied dose. — Figure 5C; Results: Testing for modulatory properties of galantamine at α7 nACh receptors expressed in HEK293 cells

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1953-04-4
Alternate CAS 69353-21-5
Applications AChE inhibitor
Formula C17H22BrNO3
Molecular Weight 368.3
Synonyms Reminyl
SMILES
COc1ccc2c3c1O[C@@H]1[C@@]3(CCN(C2)C)C=C[C@@H](C1)O.Br

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water 31 mg/mL (84.17 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
19 mg/mL
Vehicle
Saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Acharya Balkrishna, Subarna Pokhrel, Meenu Tomer, et al. Anti-Acetylcholinesterase Activities of Mono-Herbal Extracts and Exhibited Synergistic Effects of the Phytoconstituents: A Biochemical and Computational Study Molecules (2019). PMID: 31752124 DOI: 10.3390/molecules24224175 Source material
  2. [2] Natalia M Kowal, Philip K Ahring, Vivian W Y Liao, et al. Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors British Journal of Pharmacology (2018). PMID: 29669164 DOI: 10.1111/bph.14329 Source material

Added to your cart

View Cart Checkout
Loading...